Orally Disintegrating Technology Provides Both Formulating Challenges and Opportunities
Drug manufacturers today are increasingly challenged to find new, effective methods for the delivery of active pharmaceutical ingredients, and many are discovering that orally disintegrating technologies can help.
Nick Johnson, strategic marketing director for modified-release technologies at Catalent Pharma Solutions, spoke with Cynthia Challener, editor of the Pharmaceutical Sciences, Manufacturing & Marketplace Report, about orally disintegrating tablets and other technologies. The editorial podcast is here.
In Part One, Nick Johnson talks about the formulating challenges presented by orally disintegrating technologies.
In Part Two, Nick Johnson discusses current effective technologies for addressing the challenges of formulating orally disintregrating products.
In Part Three, Nick Johnson highlights some of the main drivers for the development of new orally disintegrating technologies.
In Part Four, Nick Johnson describes new technologies for orally disintegrating products that are under development in response to these market needs, including projects underway at Catalent Pharma Solutions.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
